Search

Displaying results 2031 - 2040 of 10000 in total
  1. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    Arformoterol is a bronchodilator. It works by relaxing muscles in the airways to improve breathing. … The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients

  2. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … US marketing authorization in November 2022.

  3. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

  4. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons … [L64096] The FDA approved zilganersen on September 3, 2026 for the treatment of Alexander disease in pediatric and adult patients, making it the first and only disease-modifying treatment for the condition

  5. Drug

    Diphenidol

    go.drugbank.com/drugs/DB01231
    ApprovedWithdrawn

    Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children.

  6. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    [L6652] In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy.[L41384] … It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors
  7. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older. … [L53403,L53393] It is additionally under investigation for maternal use and use in children.[A274028,L53438,L53443]

  8. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … [L49231] It is the first CRISPR-based gene editing therapy to be approved in the United States.

  9. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing. … [L1118] It was never approved by the FDA.

  10. Drug

    Allovectin-7

    go.drugbank.com/drugs/DB17439
    Investigational

    It was discontinued after it failed to improve the objective response rate or overall survival versus first-line chemotherapy in malignant melanoma.[A255207] … Allovectin-7 or allovectin-7(r) is a lipid complex that contains the DNA sequences encoding HLA-B7 and beta-2 microglobulin.